Amplia Therapeutics Limited
INNMF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Revenue | $4 | $4 | $1 | $2 |
| % Growth | -15% | 274.3% | -40% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $4 | $4 | $1 | $2 |
| % Margin | 94.4% | 90.1% | 93.8% | 99.8% |
| R&D Expenses | $8 | $6 | $5 | $4 |
| G&A Expenses | $3 | $3 | $2 | $2 |
| SG&A Expenses | $3 | $3 | $3 | $2 |
| Sales & Mktg Exp. | $0 | $0 | $1 | $0 |
| Other Operating Expenses | -$0 | -$0 | $0 | $0 |
| Operating Expenses | $10 | $8 | $7 | $6 |
| Operating Income | -$7 | -$4 | -$6 | -$4 |
| % Margin | -172.2% | -99.4% | -520.3% | -183.7% |
| Other Income/Exp. Net | -$0 | -$5 | -$0 | -$0 |
| Pre-Tax Income | -$7 | -$9 | -$6 | -$4 |
| Tax Expense | $0 | -$4 | $0 | $0 |
| Net Income | -$7 | -$5 | -$6 | -$4 |
| % Margin | -173.7% | -101.1% | -524.8% | -183.7% |
| EPS | -0.021 | -0.023 | -0.032 | -0.025 |
| % Growth | 7.8% | 28% | -28.8% | – |
| EPS Diluted | -0.021 | -0.023 | -0.032 | -0.025 |
| Weighted Avg Shares Out | 307 | 194 | 194 | 146 |
| Weighted Avg Shares Out Dil | 307 | 194 | 194 | 146 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$7 | -$5 | -$7 | -$4 |
| % Margin | -179.2% | -102.4% | -610.7% | -183.6% |